Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series.
infantile myofibroma
neonate
pharmacokinetics
therapeutic drug monitoring
vinblastine
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
14
03
2022
received:
15
02
2022
accepted:
15
03
2022
pubmed:
21
4
2022
medline:
26
5
2022
entrez:
20
4
2022
Statut:
ppublish
Résumé
Infantile myofibroma is a rare, benign tumour of infancy typically managed surgically. In a minority of cases, more aggressive disease is seen and chemotherapy with vinblastine and methotrexate may be used, although evidence for this is limited. Chemotherapy dosing in infants is challenging, and vinblastine disposition in infants is unknown. We describe the use of vinblastine therapeutic drug monitoring in four cases of infantile myofibroma. Marked inter- and intrapatient variability was observed, highlighting the poorly understood pharmacokinetics of vinblastine in children, the challenges inherent in treating neonates, and the role of adaptive dosing in optimising drug exposure in challenging situations.
Substances chimiques
Vinblastine
5V9KLZ54CY
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29722Subventions
Organisme : Cancer Research UK
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Zhao G, Zhu M, Qin C, Liu X, Zhao X. Infantile myofibromatosis: 32 patients and review of literature. J Pediatr Hematol Oncol. 2020;42:495-498.
Sparber-Sauer M, Vokuhl C, Seitz G, et al. Infantile myofibromatosis: excellent prognosis but also rare fatal progressive disease. Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry. Pediatr Blood Cancer. 2021;69:e29403.
Mahajan P, Hicks J, Chintagumpala M, Venkatramani R. Myofibroma in infancy and childhood. J Pediatr Hematol Oncol. 2017;39:e136-e139.
Levine E, Fréneaux P, Schleiermacher G, et al. Risk-adapted therapy for infantile myofibromatosis in children. Pediatr Blood Cancer. 2012;59(1):115-120.
Bidadi B, Watson A, Weigel B, Oliveira A, Kirkham J, Arndt C. Treatment of generalized infantile myofibromatosis with sorafenib and imatinib: a case report. Pediatr Blood Cancer. 2020;67(6):e28288.
Weaver MS, Navid F, Huppmann A, Meany H, Angiolillo A. Vincristine and dactinomycin in infantile myofibromatosis with a review of treatment options. J Pediatr Hematol Oncol. 2015;37:237-241.
Proust S, Benchimol G, Fraitag S, et al. Major response to imatinib and chemotherapy in a newborn patient prenatally diagnosed with generalized infantile myofibromatosis. Pediatr Blood Cancer. 2021;68(1):e28576.
Skapek SX, Ferguson WS, Granowetter L, et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group phase II trial. J Clin Oncol. 2007;25(5):501-506.
Nishida Y, Hamada S, Urakawa H, et al. Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: a phase II clinical trial. Cancer Sci. 2020;111(11):4187-4194.
Barnett S, Hellmann F, Parke E, et al. Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients. Eur J Cancer. 2022;164:127-136.
Ratain MJ, Vogelzang NJ, Sinkule JA, Chicago P. Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther. 1987;41:61-67.
Owellen R, Hartke C, Hains F. Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res. 1977;37:2597-2602.
Nijstad AL, Barnett S, Lalmohamed A, et al. Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance. Eur J Cancer. 2022;164:137-154.
Adamson PC. It's not easy being small. Pediatr Blood Cancer. 2010;54:341-343.
Veal GJ, Boddy AV. Chemotherapy in newborns and preterm babies. Semin Fetal Neonatal Med. 2012;17(4):243-248.
Veal GJ, Errington J, Hayden J, et al. Carboplatin therapeutic monitoring in preterm and full-term neonates. Eur J Cancer. 2015;51(14):2022-2030.
Zhou-Pan XR, Sérée E, Zhou XJ, et al. Involvement of human liver cytochrome P4503A in vinblastine metabolism: drug interactions. Cancer Res. 1993;53:5121-5126.
Horio M, Gottesman MM, Pastan I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA. 1988;85:3580-3584.
de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinetic. 1999;37(6):485-505.
Brouwer KLR, Aleksunes LM, Brandys B, et al. Human ontogeny of drug transporters: review and recommendations of the pediatric transporter working group. Clin Pharmacol Ther. 2015;98(3):266-287.